The effect of ibudilast on thalamic volume in progressive multiple sclerosis.

ABSTRACT:

Background

Thalamic volume loss is known to be associated with clinical and cognitive disability in progressive multiple sclerosis (PMS).

Objective

To investigate the treatment effect of ibudilast on thalamic atrophy more than 96 weeks in the phase 2 trial in progressive(MS Secondary and Primary Progressive Ibudilast NeuroNEXT Trial in Multiple Sclerosis [SPRINT-MS]).

Methods

A total of 231 participants were randomized to either ibudilast (n = 114) or placebo (n = 117). Thalamic volume change was computed using Bayesian Sequence Adaptive Multimodal Segmentation tool (SAMseg) incorporating T1, fluid-attenuated inversion recovery (FLAIR), and fractional anisotropy maps and analyzed with a mixed-effects repeated-measures model.

Results

There was no s

SUBMITTER: Nicholson S 

PROVIDER: S-EPMC10841081 | biostudies-literature | 2023 Dec

REPOSITORIES: biostudies-literature